University of Colorado-Boulder researchers developing next-generation vaccines, drugs to protect against cardiac diseases and other research have been selected to receive grants from the Colorado Bioscience Discovery Evaluation Grant Program.

July 18-19th | Charlottesville, VA
The University Gap Fund/Accelerator Summit
0
0
0
0
Days
0
0
Hrs
0
0
Min
0
0
Sec

The Colorado Office of Economic Development and International Trade established the grant program in 2007.

“The BDEG program provides a powerful catalyst to get these ideas out of their academic institutions and into the marketplace,” professor Tom Cech, director of CU’s BioFrontiers Institute, said in a release. Four of the 10 researchers or research teams are based at CU-Boulder, including three in the BioFrontiers Institute.

The grants include “proof-of-concept” grants to move promising biotechnologies closer to market readiness and early-stage matching “seed” grants to enable the development and commercial validation of technologies that are licensed from Colorado research institutions by Colorado based start-up companies, according to a press release from the University of Colorado Technology Transfer Office.

The four CU research projects that have received or will soon receive funding in the 2011-12 round are:

Christopher Bowman, Department of Chemical and Biological Engineering, CU-Boulder, for inexpensive, highly efficient synthetic nucleic acids for use in nanoassembly, biodetection and other biofunctional applications.

Robert Garcea, BioFrontiers Institute, Department of Molecular, Cellular and Developmental Biology, CU-Boulder, for a next-generation vaccine for human papillomavirus (HPV).

Leslie Leinwand, BioFrontiers Institute, Department of Molecular, Cellular and Developmental Biology, CU-Boulder, for novel drugs to offer protection from cardiac disease.

Hang (Hubert) Yin, BioFrontiers Institute, Department of Chemistry and Biochemistry, CU-Boulder, for more sensitive biomarkers for metastatic cancers and other diseases in body fluids.

RELATED: 

U Colorado/State of Colorado matching fund supports seven bioscience companies